Parr Mcknight Wealth Management Group LLC Purchases 9,682 Shares of Zoetis Inc. $ZTS

Parr Mcknight Wealth Management Group LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 113.8% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 18,191 shares of the company’s stock after purchasing an additional 9,682 shares during the quarter. Parr Mcknight Wealth Management Group LLC’s holdings in Zoetis were worth $2,150,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis during the fourth quarter valued at approximately $25,000. Prosperity Bancshares Inc purchased a new position in Zoetis in the 4th quarter worth approximately $25,000. Lodestone Wealth Management LLC purchased a new position in Zoetis in the 4th quarter worth approximately $30,000. Root Financial Partners LLC lifted its position in Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares in the last quarter. Finally, KERR FINANCIAL PLANNING Corp bought a new position in Zoetis in the 3rd quarter valued at approximately $31,000. 92.80% of the stock is currently owned by institutional investors.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
• Neutral Sentiment: Multiple law firms, including Rosen, Glancy Prongay, Bragar Eagel & Squire, The Gross Law Firm, Kessler Topaz, Schall, Howard G. Smith, and Bernstein Liebhard, are urging investors who bought ZTS shares during the class period to contact them before the July 27 lead plaintiff deadline.
• Negative Sentiment: A class action lawsuit has been filed against Zoetis and certain officers, with allegations of material misstatements and/or omissions tied to product adoption, which may increase legal costs and pressure the stock. Article Title

Insider Buying and Selling

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were acquired at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Michael B. Mccallister purchased 3,000 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the purchase, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have acquired 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by insiders.

Zoetis Stock Performance

Shares of ZTS opened at $75.49 on Monday. The firm has a market capitalization of $31.65 billion, a P/E ratio of 12.52, a PEG ratio of 1.18 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a one year low of $71.47 and a one year high of $160.48. The business has a fifty day moving average of $79.96 and a 200 day moving average of $107.64.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The firm had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The firm’s revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the company posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.16%.

Wall Street Analyst Weigh In

A number of research firms have commented on ZTS. Morgan Stanley reissued an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a report on Friday, May 15th. Stifel Nicolaus dropped their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research report on Friday, June 26th. TD Cowen dropped their price objective on Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. HSBC reduced their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a report on Monday, July 6th. Finally, Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $123.46.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.